Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma

Launched by SUN YAT-SEN UNIVERSITY · Dec 11, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment for patients with thymoma, a type of tumor that forms in the thymus gland and can sometimes be difficult to treat. Specifically, the study is looking at how well a medication called methylprednisolone works when combined with chemotherapy and radiation therapy for patients whose thymoma cannot be surgically removed or has come back after treatment. The researchers want to see if this combination can help shrink the tumor or improve outcomes for these patients.

To be eligible for the study, participants must be between 18 and 70 years old and have a confirmed diagnosis of a specific type of thymoma that can be measured. They should have tumors that are confined to the chest and neck and have not received previous radiation to the chest. Participants will need to be in generally good health, meaning they can perform daily activities without major issues. Those with certain health conditions or who are pregnant will not be able to join. If you choose to participate, you can expect close monitoring by healthcare professionals throughout the trial, and you will need to provide informed consent before starting. This is an important step to ensure that you understand what the study involves and agree to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically confirmed type AB or B1-3 thymoma.
• • Measurable Disease: Patients must have measurable disease as defined by RECIST (Response Evaluation Criteria in Solid Tumors).
• • Unresectable or recurrent thymoma, with the tumor confined to the chest and neck area.
• • Between the ages of 18 and 70 years, regardless of sex.
• • Eastern Cooperative Oncology Group performance status of 0 or 1.
• • No prior chest radiation.
• • Adequate organ Functions.
• • Written informed consent obtained.
• Exclusion Criteria:
• • Contraindications to Methylprednisolone.
• • History of or Concurrent Malignancy.
• • Active infection, myocardial infarction within the last 6 months or symptomatic heart disease.
• • Pregnant or Lactating Women.
• • Bleeding Disorders.
• • Recent Participation in Other Clinical Trials.
• • Drug Abuse or Severe Alcoholism.
• • Uncontrolled Seizures or Mental Disorders.
• • Severe Allergies or Specific Sensitivities.